Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11072786 | 0.78 | P2RX7 (0.40) | P2RX7MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL5698980 | 0.76 | P2RX7 (0.39) | P2RX7MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL24113945 | 0.76 | P2RX7 (0.39) | P2RX7MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL23489779 | 0.76 | P2RX7 (0.39) | P2RX7MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL15927758 | 0.76 | P2RX7 (0.39) | P2RX7MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL23563872 | 0.74 | NOS3 (0.41) | P2RX7MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL23830227 | 0.73 | P2RX7 (0.53) | P2RX7MKNK1MKNK2KDM4EGAA | |
| SCHEMBL22545223 | 0.72 | CYP1A2 (0.41) | P2RX7MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL3290076 | 0.72 | CYP1A2 (0.41) | P2RX7MKNK1MKNK2NOS3NOS1 | |
| SCHEMBL29945659 | 0.72 | CYP1A2 (0.41) | P2RX7MKNK1MKNK2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745286-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | P2RX7 112/4885MKNK1 742/4885MKNK2 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.